Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013183" target="_blank" >RIV/00023736:_____/21:00013183 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/21:10422841

Výsledek na webu

<a href="https://doi.org/10.3390/ph14010041" target="_blank" >https://doi.org/10.3390/ph14010041</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ph14010041" target="_blank" >10.3390/ph14010041</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

Popis výsledku v původním jazyce

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS patients and those who were given DFX treatment. The gene expression profiles of bone marrow CD34+ cells were assessed by whole-genome microarrays. Initially, differentially expressed genes (DEGs) were determined between patients with normal ferritin levels and those with IO to address the effect of excessive iron on cellular pathways. These data indicate DFX modulates the immune response mainly via neutrophil-related genes. Suppression of negative regulators of blood cell differentiation essential for cell maturation and upregulation of heme metabolism observed in DFX-treated patients may contribute to the hematopoietic improvement.

Název v anglickém jazyce

Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

Popis výsledku anglicky

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS patients and those who were given DFX treatment. The gene expression profiles of bone marrow CD34+ cells were assessed by whole-genome microarrays. Initially, differentially expressed genes (DEGs) were determined between patients with normal ferritin levels and those with IO to address the effect of excessive iron on cellular pathways. These data indicate DFX modulates the immune response mainly via neutrophil-related genes. Suppression of negative regulators of blood cell differentiation essential for cell maturation and upregulation of heme metabolism observed in DFX-treated patients may contribute to the hematopoietic improvement.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV16-31689A" target="_blank" >NV16-31689A: Protinádorové účinky chelatační léčby u myelodysplastického syndromu a identifikace nových terapeutických biomarkerů.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmaceuticals

ISSN

1424-8247

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

14

Strana od-do

"art. no. 41"

Kód UT WoS článku

000610681000001

EID výsledku v databázi Scopus

2-s2.0-85099764158